SWOG clinical trial number
SWOG-8903
Phase I Trial of Promace-CytoBOM with GM-CSF for Treatment of Non-Hodgkin's Lymphoma
Closed
Phase
Accrual
93%
Published
Abbreviated Title
Phase I Trial of Promace-CytoBOM with GM-CSF for Treatment of Non-Hodgkin's Lymphoma
Activated
11/15/1989
Closed
11/01/1993
Research committees
Lymphoma
Publication Information Expand/Collapse
2003
Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate and high grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349)
Other Clinical Trials
SWOG Clinical Trial Number
S2207
Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma
Research Committee(s)
Lymphoma
Activated
06/30/2023
Accrual
6%
Open
Phase
SWOG Clinical Trial Number
CTSU/AHOD2131
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Research Committee(s)
Lymphoma
Immunomolecular Therapeutics
Activated
04/28/2023
Open
Phase
SWOG Clinical Trial Number
S2114
A Randomized Phase II trial of consolidation therapy following CD19 CAR T-cell treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
02/23/2023
Accrual
12%
Open
Phase